Replies to post #81538 on Biotech Values

[srsmgja]

Not a word in the press release regarding UNIT SALES of copaxone. I wonder why that detail was left out? Perhaps they'll mention it on the conference call.

I still contend that the overwhelming majority of this sales increase is due to the 30% YEARLY increases over the last 3 years. These price increases are not sustainable, IMO

[zipjet]

Copaxone vs Tysabri in the US Market

Or you could say sequential growth in the latest Q was:

Copaxone 1.9%
Tysabri 7.7%

Unless there was a price increase for Tysabri or some other distortion, Tysabri performed relatively better.

IF the neuro's treating MS get more comfortable with the PML risk, Tysabri could gain a lot on it's superior patient outcomes.

Thanks for the data table.

ij

[masterlongevity]

copaxone is cleaning avonex's clock too.

[alertmeipp]

But if u look at just the last couple quarters... Tysabri is superior. :)

We will have to wait next few quarters to see those PML events is impacting the growth.